Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT®) for women with menopausal symptoms

PharmacoEconomics

Volumn 21, Issue 9, 2003, Pages 661-669

  Coyle, Douglas ^a,b   Cranney, Ann ^a   Tugwell, Peter ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; FEMHRT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HIP FRACTURE; HUMAN; LIFE EXPECTANCY; LIFESPAN; MENOPAUSAL SYNDROME; MONEY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SYMPTOM; VAGINA BLEEDING;

EID: 0038352129     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321090-00004     Document Type: Article

References (32)

1. Speroff L, Symons J, Kempfert J, et al. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (FemHRT®) on the frequency and intensity of vasomotor symptoms. Menopause 2000; 7: 383-90
2. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37
3. Karakoc B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998; 5: 102-6
4. Ryan PJ, Harrison R, Blake GM, et al. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynecol 1992; 99: 325-8
5. Hill DA, Weiss NS, LaCroix AZ. Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study. Am J Obstet Gynecol 2000; 182: 270-6
6. Samsioe G. Hormone replacement therapy: aspects of bleeding problems and compliance. Int J Fertil Menopausal Stud 1996; 41: 11-5
7. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86: 306-16
8. Doren M, Reuther G, Minne HW, et al. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in post-menopausal women. Am J Obstet Gynecol 1995; 173: 1446-51
9. Symons J, Kempfert N, Speroff L. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. Obstet Gynecol 2000; 96 (3): 366-72
10. Cheung AP, Wren BG. A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 1992; 156 (5): 312-6
11. Torgerson DJ, Reid DM. The pharmacoeconomics of hormone replacement therapy. Pharmacoeconomics 1999; 16 (1): 9-16
12. Weinstein MC, Tosteson AN. Cost-effectiveness of hormone replacement. Ann N Y Acad Sci 1990; 592: 162-72
13. Daly E, Roche M, Barlow D, et al. HRT: an analysis of benefits, risks and costs. Br Med Bull 1992; 48 (2): 368-400
14. US Congress, Office of Technology Assessment. Effectiveness and costs of osteoporosis screening and hormone replacement therapy: vol 1: cost-effectiveness analysis. OTA-BP-H-160. Washington DC: US Government Printing Office, 1995
15. Weinstein MC, Schiff I. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 1983; 38 (8): 445-55
16. Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 1996; 6 (4): 265-75
17. Coyle D, Cranney A, Lee KM, et al. Cost-effectiveness of nasal calcitonin in postmenopausal women: using Cochrane Collaboration methods for meta analysis in economic evaluation. Pharmacoeconomics 2001; 19 (5 Pt 2): 565-75
18. Jonsson B, Christiansen C, Johnell O, et al. Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 1995; 5 (2): 136-42
19. Torgerson D, Kanis JA. Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. Q J Med 1995; 88: 135-9
20. CCOHTA Guidelines for the economic evaluation of pharmaceuticals. Ottawa: CCOHTA, 1997
21. Gold M, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
22. Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Am J Obstet Gynecol 1999; 181: 71-9
23. Greendale GA, Reboussin HA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol 1998; 92: 982-8
24. Papadimitroupoulos EA, Coyte PC, Josse RG, et al. Current and projected rates of hip fractures in Canada. CMAJ 1997; 157 (10): 1537-66
25. Wells, GA, Tugwell P, Shea BJ et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2001; 23: 529-39
26. Statistics Canada. Life tables, Canada and provinces, 1990-92. 84-537 occasional. Ottawa: Statistics Canada, 1995
27. Ontario Ministry, of Health. Ontario drug benefit formulary. Toronto (ON): Ministry of Health and Long Term Care, 1999
28. Wiktorowicz ME, Goeree R, Papaioannou A, et al. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 2001; 12 (4): 271-8
29. Feeny D, Furling W, Boyle M, et al. Multi-attribute health status classification systems: Health Utilities Index. Pharmacoeconomics 1995; 7 (6): 490-502
30. Cranney A, Coyle D, Pham B, et al. The psychometric properties of patient preferences in osteoporosis. J Rheumatol 2001; 28: 132-7
31. Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993; 307: 836-40
32. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial, JAMA. 2002; 288: 321-33